Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

An observational study of Pseudomonas aeruginosa in adult long-term ventilation

Ruth Sobala, Hannah Carlin, Thomas Fretwell, Sufyan Shakir, Katie Cattermole, Amy Royston, Paul McCallion, John Davison, Joanna Lumb, Hilary Tedd, Ben Messer, Anthony De Soyza
ERJ Open Research 2022 8: 00687-2021; DOI: 10.1183/23120541.00687-2021
Ruth Sobala
1North East Assisted Ventilation Service, Newcastle Upon Tyne Hospitals Trust, Newcastle, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ruth Sobala
  • For correspondence: Ruth.sobala1@nhs.net
Hannah Carlin
1North East Assisted Ventilation Service, Newcastle Upon Tyne Hospitals Trust, Newcastle, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Fretwell
1North East Assisted Ventilation Service, Newcastle Upon Tyne Hospitals Trust, Newcastle, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sufyan Shakir
1North East Assisted Ventilation Service, Newcastle Upon Tyne Hospitals Trust, Newcastle, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katie Cattermole
1North East Assisted Ventilation Service, Newcastle Upon Tyne Hospitals Trust, Newcastle, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amy Royston
1North East Assisted Ventilation Service, Newcastle Upon Tyne Hospitals Trust, Newcastle, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Amy Royston
Paul McCallion
2Freeman Hospital, Newcastle, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Paul McCallion
John Davison
2Freeman Hospital, Newcastle, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joanna Lumb
2Freeman Hospital, Newcastle, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hilary Tedd
1North East Assisted Ventilation Service, Newcastle Upon Tyne Hospitals Trust, Newcastle, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ben Messer
1North East Assisted Ventilation Service, Newcastle Upon Tyne Hospitals Trust, Newcastle, UK
4These authors contributed equally
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony De Soyza
1North East Assisted Ventilation Service, Newcastle Upon Tyne Hospitals Trust, Newcastle, UK
2Freeman Hospital, Newcastle, UK
3Population Health Science Institutes, Newcastle University, Newcastle, UK
4These authors contributed equally
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Introduction Pseudomonas aeruginosa increases morbidity and mortality in respiratory disease. To date the long-term ventilation population does not have clear guidelines regarding its management.

Method We undertook a retrospective observational study in a regional long-term ventilation population (837 patients). We defined the primary outcome as P. aeruginosa isolation. In addition positive cultures for copathogens (Serratia, Proteus species, Stenotrophomonas, Burkholderia cepacia complex and nontuberculous mycobacteria) were recorded. Logistic regression and odds ratios were calculated.

Results 17.6% of the cohort isolated P. aeruginosa, and this pathogen was cultured more frequently in patients with a tracheostomy (logistic regression coefficient 2.90, p≤0.0001) and cystic fibrosis/bronchiectasis (logistic regression coefficient 2.48, p≤0.0001). 6.3% of patients were ventilated via tracheostomy. In the P. aeruginosa positive cohort 46.9% of patients were treated with a long-term macrolide, 36.7% received a nebulised antibiotic and 21.1% received both. Tracheostomised P. aeruginosa positive patients received a nebulised antibiotic more frequently (OR 2.63, 95% CI 1.23–5.64, p=0.013). Copathogens were isolated in 33.3% of the P. aeruginosa cohort. In this cohort patients with a tracheostomy grew a copathogen more frequently than those without (OR 2.75, 95% CI 1.28–5.90).

Conclusions P. aeruginosa isolation is common within the adult long-term ventilation population and is significantly associated with tracheostomy, cystic fibrosis and bronchiectasis. Further research and international guidelines are needed to establish the prognostic impact of P. aeruginosa and to guide on antimicrobial management. The increased risk of P. aeruginosa should be considered when contemplating long-term ventilation via tracheostomy.

Abstract

Pseudomonas aeruginosa isolation is common (17%) in long-term ventilated adults and significantly associated with tracheostomy, cystic fibrosis and bronchiectasis. Tracheostomy patients with P. aeruginosa isolates culture copathogens more frequently. https://bit.ly/3vvxBbB

Introduction

Pseudomonas aeruginosa (Pa) is a well-recognised opportunistic Gram-negative respiratory pathogen affecting a number of patient groups with underlying respiratory diseases. These include patients with COPD, bronchiectasis and cystic fibrosis (CF). It drives both morbidity [1] and early mortality [2] in the latter two diseases leading to guideline recommendations to conduct surveillance for detecting this pathogen [3, 4]. Additionally guidelines recommend the use of either systemic (e.g. long-term macrolides) or pulmonary-targeted antibiotic therapies (e.g. nebulised antibiotics) to reduce exacerbation rates [3, 4].

Home long-term ventilation (LTV) services have a diverse range of aetiologies under their care. Common indications include congenital muscular dystrophies such as Duchenne muscular dystrophy (DMD), acquired neuromuscular disorders such as motor neurone disease (MND), restrictive chest wall conditions such as kyphoscoliosis, diaphragm palsy, sleep disordered breathing, obesity hypoventilation syndrome (OHS) and respiratory diseases such as those documented above.

In acute illness, when invasive ventilation is required, there is an increased risk of Pa infection, i.e. ventilator-associated pneumonia, and data for patients chronically invasively ventilated in a home care setting suggest Pa is common within a year of discharge [5].

Improving survival rates on LTV (both invasive and noninvasive), has resulted in increasingly complex patients being managed by LTV services. These patients are managed by specialist centres. However, there is minimal literature on the burden of Pa in those requiring home LTV. In the absence of guidelines on managing this infection outside of CF and bronchiectasis [3, 4] we sought to describe both the prevalence of Pa in our home ventilation cohort and the management strategies applied.

Material and methods

Study population

We undertook a retrospective observational study on a regional LTV population. The service covers the North East and Cumbria, with a population of 3 million. It is the primary care provider for LTV patients in the region and receives referrals from 11 hospitals. Three satellite clinics are required.

The population of patients was identified using the regional LTV database. At the time of access (March 2021) the database consisted of 837 active adult patients. LTV care was defined as receiving noninvasive ventilation (NIV), mechanical insufflation–exsufflation (MI-E), both treatments or high-flow nasal cannula. The database contained the indication for LTV.

Data collection

Electronic medical records at our hospital and referring units were accessed to record the additional information: Pa cultured ever, Pa cultured in the last 2 years, Pa treated with a nebulised antibiotic or a long-term macrolide, presence of tracheostomy for ventilation, requirement for long-term oxygen therapy (LTOT) or ambulatory oxygen therapy (AOT), and prescription of the mucolytic carbocisteine.

Patients were grouped according to individual diagnosis or categories as follows: airway disease (asthma/COPD), CF/bronchiectasis, interstitial lung diseases, restrictive chest wall conditions, diaphragm palsy, OHS and obstructive sleep apnoea (OSA), MND, DMD, all other neuromuscular disease (e.g. myopathies and dystrophies), cerebral palsy, spinal cord injury, other neurological conditions and other (i.e. miscellaneous) (see supplementary appendix 1). Patients with COPD–OSA overlap were included within the airway disease category.

We defined the primary outcome as Pa colonisation, identified through historical or current respiratory culture results. In view of the common inherent resistance of certain bacterial species to colistin (colistimethate sodium) we also recorded any present or historically positive cultures for Serratia, Proteus species, Stenotrophomonas, Burkholderia cepacia complex and nontuberculous mycobacteria (NTM).

Data analysis

We described observed frequencies and compared distributions using odds ratios. A logistic regression was performed (Mathematica, Version 12.3.1; Wolfram Research Inc., Champaign, IL, USA (2021)) to determine the independent effects of disease type and the presence/absence of tracheostomy on Pa isolates.

Results

We identified 837 patients under the regional LTV service and accessed present and historical microbiology results for all of them. 6.3% were ventilated via tracheostomy. 17.6% were culture positive for Pa (from airway samples: sputum, tracheal aspirates, bronchial lavage) and 8.6% culture positive within the last 24 months. Within the Pa positive cohort the mean age was 52 years with male:female ratio 1.88:1, reflecting the male dominant disease pattern of several LTV conditions. At time of data gathering (March 2021) patients had received ventilation for a mean of 1828 days (5 years). 36.1% of Pa positive patients were on both LTV and MI-E, 18.4% solely on MI-E and 6.8% used a lung volume recruitment bag in addition to LTV. Two patients received ventilation via high-flow nasal cannula.

Patients with CF and patients with tracheostomy had the highest prevalence of Pa colonisation (74.2% and 71.7% respectively). Spinal cord injury and the grouping “other” (e.g. ventilatory failure of unknown origin, global developmental delay, etc.) had the highest numbers of tracheostomy patients. Patients with primary respiratory diseases (COPD, asthma, bronchiectasis, CF) did not require tracheostomy. 33.3% of patients using an MI-E device had positive Pa isolates.

Demographic and clinical data are described in table 1, including the prevalence of Pa by diagnostic subgroup, and by tracheostomy. The prevalence of Pa in patients with CF/bronchiectasis was high, as expected (74.2%); however, there was also a high burden of disease in patients with spinal cord injuries (40.0%), other (33.3%), cerebral palsy (31.6%) and DMD (26.9%).

View this table:
  • View inline
  • View popup
TABLE 1

Clinical data

Logistic regression (LR) was performed to account for the confounding variables created by tracheostomy and disease group (see table 2). This identified tracheostomy as being the strongest positive factor associated with Pa (LR coefficient 2.90, p≤0.0001). Patients with CF/bronchiectasis also had a positive association (LR coefficient 2.48, p≤0.0001). Patients with cerebral palsy had a non-significant but positive coefficient (LR coefficient 0.65, p=0.302). In contrast, MND and OHS/OSA were negatively associated with the presence of Pa culture (LR coefficient −2.14, p=0.004, and −1.83, p=0.001, respectively).

View this table:
  • View inline
  • View popup
TABLE 2

Logistic regression

Isolates of copathogens

Commencement of a nebulised antibiotic had limited documentation, which hindered assessment of Pa suppression or effects on emerging pathogens. Serratia, Proteus species, Stenotrophomonas, Burkholderia cepacia complex and NTM were isolated in 8.5% of the LTV cohort and 33.3% of the Pa cohort. In the Pa cohort the copathogens cultured most frequently were Serratia (15.0%) and Stenotrophomonas (11.6%). Culture of copathogens was more frequent in patients colonised with Pa (OR 15.18, 95% CI 8.80–26.21, p≤0.0001) (see table 3).

View this table:
  • View inline
  • View popup
TABLE 3

Culture positive for copathogens

The proportion of patients with one or more positive copathogen was highest in the patient groups CF/bronchiectasis (35.5%) and spinal cord injury (28.9%). Logistic regression to account for tracheostomy bias was not performed due to small sample size. However, there were no tracheostomy patients in the CF/bronchiectasis grouping but six in the spinal cord injury group.

52.7% of patients treated with a nebulised antibiotic grew copathogens.

Management and treatment patterns

In the Pa cohort 46.9% of patients received a long-term macrolide and 36.7% received a nebulised antibiotic. 21.1% patients received both a nebulised antibiotic and a long-term macrolide.

Azithromycin was prescribed in 18.5% of total patients and 46.9% of the Pa cohort. Pa colonisation was more common in patients prescribed azithromycin (OR 6.21, 95% CI 4.19–9.22, p≤0.0001).

36.7% of the Pa positive cohort were treated with a nebulised antibiotic. Colistin was the most frequently prescribed antibiotic (85.2%) (see figure 1).

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Nebulised antibiotic prescribed.

In the tracheostomised Pa positive cohort, patients received a nebulised antibiotic more frequently (OR 2.63, 95% CI 1.23–5.64, p=0.013), and were colonised with a copathogen more often (OR 2.75, 95% CI 1.28–5.90, p=0.01) than Pa positive patients without a tracheostomy. Fewer patients in this group received azithromycin, but this difference was not significant (OR 0.61, 95% CI 0.28–1.30, p=0.202) (see table 4).

View this table:
  • View inline
  • View popup
TABLE 4

Pa culture positive group

21.5% of all patients received LTOT and/or AOT, while in the Pa positive cohort 30.6% of patients received LTOT and/or AOT. Pa colonisation was more common in patients with LTOT and/or AOT (OR 1.84, 95% CI 1.23–2.73, p=0.003).

Carbocisteine was prescribed in 27.6% of total patients and 51.7% of the Pa positive cohort. Pa colonisation was more common in patients prescribed carbocisteine (OR 3.69, 95% CI 2.55–5.35, p<0.0001) (see table 5).

View this table:
  • View inline
  • View popup
TABLE 5

Other management

Discussion

Pseudomonas aeruginosa is a ubiquitous organism found in the natural environment but is frequently associated with both acute and chronic infections of the respiratory tract [6]. Recent paediatric research suggested a 15% prevalence of Pa in children with complex neuromuscular disorders and cerebral palsy [7]. The pathogen colonised 11% of a paediatric LTV cohort and reached a prevalence of 63% in LTV paediatric patients with a tracheostomy [7].

The current study is, to our knowledge, the first extensive work on Pa isolates in an adult LTV cohort. Our key findings are that Pa colonisation is frequent in adults on LTV, affecting nearly 1 in 5 (17.6%). Consistent with previous data [7], we found that tracheostomy is a significant factor influencing Pa positive culture. Patients with CF and bronchiectasis also had high Pa culture rates, an expected result as this pathogen is associated with these diseases. It is therefore expected to be intensified in a population with high disease severity requiring LTV [2]. Lastly, patients with a tracheostomy who were colonised with Pa were more likely to receive treatment in the form of a nebulised antibiotic and have samples positive for copathogens (Serratia, Proteus species, Stenotrophomonas, Burkholderia cepacia complex and NTM).

The frequency of Pa in the tracheostomy population was 71.7%, a higher rate than documented in previous paediatric studies [7]. Consistent with previous data [7], we also observed high rates of Pa in the cohort with cerebral palsy, but these results were not significant. This likely reflects the small sample size in this group (19). Interestingly no patients with cerebral palsy had a tracheostomy.

Patients with OSA/OHS and MND were associated with a statistically significantly lower probability of culturing Pa isolates. This outcome is not unexpected. LTV for OHS is associated with a reduced mortality (5-year survival 77.3%) than in untreated OHS [8]. High NIV adherence results in less hospital admission, and improved mortality [9]. We postulate that due to the rapid progression and reduced life expectancy in MND, the time period on LTV may be short, with lower lifetime antibiotic exposure and less time for acquisition of Pa. Further research into the reduced frequency of Pa in these disease categories is welcomed.

LTV services care for a diverse number of aetiologies. Since tracheostomy is associated with increased rates of Pa, a useful tool for home ventilation clinicians is to understand which disease categories have higher rates of tracheostomy. We found patients with spinal cord injury had the highest prevalence of tracheostomy, followed by the groups “other” and DMD.

Nearly half of Pa positive patients received treatment in the form of a long-term macrolide, and over a third received a nebulised antibiotic. Macrolide and nebulised antibiotic use are recommended in guidelines for preventing Pa-associated respiratory exacerbations for both bronchiectasis and CF. These agents are not specifically recommended in neuromuscular disease guidelines, and hence treatment is often empirical [10, 11]. There is a potential for these modalities to cause harm; colistin has been associated with respiratory arrest in myasthenia gravis [12] but also potential benefit, i.e. reducing/preventing Pa infections [12]. The clinical rationale for commencing antibiotic treatment in our cohort was not analysed, nor was exacerbation rate secondary to Pa infection, or the prevalence of Pa-associated pneumonia. A recent paediatric series [7] showed there was no immediate treatment benefit to acute anti-pseudomonals versus empirical antibiotics, highlighting the need for further research and understanding in this area.

There has been limited research regarding the prognostic significance of Pa in those with long-term tracheostomies [13, 14]. Pa has been shown to colonise tracheostomy tubes, forming biofilms [15]. Biofilms are recognised to cause an inherent resistance to antimicrobial treatment as well as bacterial persistence [7, 15]. Furthermore there is evidence of transmission to the lower airways resulting in complications such as pneumonia [16, 17]. As there are no clear guidelines for the management of Pa in long-term tracheostomy, treatment is guided by the patient's clinical presentation and physicians’ acumen. In the acute ventilation setting there is a tendency to treat, reflecting the critical illness of these patients and the priority to prevent ventilator-associated pneumonia. We recorded a significant increase in treatment with a nebulised antibiotic in our Pa tracheostomy population (54.1%) but are unable to conclude whether this was guided by patients’ clinical deterioration/biochemical markers or solely triggered by the presence of tracheostomy. Another important variable to consider is sampling bias, and that tracheostomised patients may have sputum cultures sent more frequently as part of secretion management or for intentional surveillance.

There was a wide range in treatment modalities used in the management of these patients. This included combinations of and isolated use of long-term macrolides, nebulised colistin, nebulised aminoglycosides, cyclical nebulised antibiotic, e.g. tobramycin/colistin, and widespread use of carbocisteine as a mucolytic agent. It is important to recognise that prescription does not reflect adherence to treatment. Adherence to long-term nebulised antibiotic therapy can be challenging, and patients requiring LTV already have a significant treatment burden.

Within the Pa isolate cohort requirement for LTOT and/or AOT was not independent of diagnostic group. 80% of patients on LTOT and/or AOT had a respiratory diagnosis.

The exact date of commencement of a nebulised antibiotic had limited documentation, which hindered assessment of Pa suppression or effects on emerging pathogens. Similarly the COVID-19 pandemic has limited sputum sample collections as clinics carried out more remote consultations in 2020–2021. Within the cohort of Pa positive isolates, we had hoped to record the infective exacerbation rate pre- and post-treatment with Pa eradication antimicrobials. However, a key limitation to our study, reflecting the retrospective design, was the lack of documentation of this.

We found that Serratia, Proteus species, Stenotrophomonas, Burkholderia cepacia complex or NTM were isolated in 33.3% of the Pa cohort, and patients with a tracheostomy and Pa isolates were at increased risk of culturing a copathogen. This reflects the known association between tracheostomy and bacterial colonisation. A limitation to this research is we did not record the time period between isolating Pa and the copathogen. We recognise that the two isolates may have a significant time period between them. It is also possible the copathogen predates the first Pa isolate. NTM prevalence may be underestimated as growth requires rapid-growing mycobacteria medium to be specifically requested. The regional nature of the study resulted in samples being accessed across multiple sites and microbiology laboratories. These naturally will have slight variation in their approach to sample preparation.

An important question requiring further assessment is whether long-term antibiotics in LTV and LTV tracheostomy results in increased rates of virulent copathogens (i.e. multiple drug-resistant bacteria). Secondly, do long-term antimicrobials suppress Pa and/or exacerbation rates in this cohort? This is a point of major interest for the home ventilation community and also for antibiotic stewardship. It is important to balance treating infection against the potential future harm from antibiotic resistance.

The strengths of this study are the large sample size, data collection across multiple organisations and the description of treatment modalities applied. There are, however, limitations that need to be recognised, predominantly related to the retrospective design. Firstly, we cannot conclude that the prevalence described here is truly representative – if a sample has not been requested as part of routine clinical assessment, we cannot confirm the absence of Pa. Secondly, from the data gathered we do not know what proportion of Pa isolates represent asymptomatic colonisation versus a pathogen driving clinical deterioration. However, a degree of pragmatism is required when studying patients receiving LTV, acknowledging the reduced life expectancy seen in some subgroups which can make prospective study design challenging. Thirdly, although this was a regional study, we still encountered multiple aetiologies with small (n=1) cohorts (see supplementary material). This reflects the diversity of aetiologies managed by LTV services. In order to overcome this barrier a multicentre approach to data collection would be required. Additionally, we acknowledge that a valued piece of data would be the time period on LTV and/or tracheostomy to the first isolate of Pa. Lastly, although infrequent, our service has patients who require home ventilation following a failed wean and level 3 intensive care. In the immediate period following discharge these patients may be colonised with hospital acquired bacteria. However, the mean number of days before the first episode of ventilator-associated pneumonia in home ventilation is 345 days suggesting a complex relationship between culture status and major infection episodes [5].

We conclude that Pa positive culture is common within the adult LTV population and is significantly associated with the presence of tracheostomy. This is an important consideration, adding to the high rates of healthcare burden already seen in this population [18] Patients managed with LTV, particularly those with a tracheostomy, should be considered for surveillance sputum culture as is already applied in other at-risk groups such as bronchiectasis. Research is required into whether Pa isolated in the adult LTV population drives morbidity and/or mortality, as seen in other diseases such as COPD and bronchiectasis [1, 2, 19]. This evidence will help formulate international guidelines on long-term antimicrobial management. Finally, when considering whether to proceed with tracheostomy in a LTV setting, the higher risk of Pa isolates and attendant treatment burden (i.e. limited oral or enteral antibiotic choices) should be discussed during multidisciplinary team meetings and shared decision making with the patient.

Supplementary material

Supplementary Material

Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.

Supplementary material 00687-2021.SUPPLEMENT

Footnotes

  • Provenance: Submitted article, peer reviewed.

  • Conflict of interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. B. Messer reports speakers’ fees from Fisher and Paykel outside the submitted work. A. De Soyza has received fees/grants from AstraZeneca, Bayer, GSK, Novartis, Grifols, Gilead and Zambon.

  • Received December 6, 2021.
  • Accepted February 22, 2022.
  • Copyright ©The authors 2022
http://creativecommons.org/licenses/by-nc/4.0/

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org

References

  1. ↵
    1. Chalmers J,
    2. Aliberti S,
    3. Filonenko A, et al.
    Characterization of the “frequent exacerbator phenotype” in bronchiectasis. Am J Respir Crit Care Med 2018; 197: 1410–1420. doi:10.1164/rccm.201711-2202OC
    OpenUrl
  2. ↵
    1. Finch S,
    2. McDonnell M,
    3. Abo-Leyah H, et al.
    A Comprehensive analysis of the impact of Pseudomonas aeruginosa colonisation on prognosis in adult bronchiectasis. Ann Am Thorac Soc 2015; 12: 1602–1611.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Hill AT,
    2. Sullivan AL,
    3. Chalmers JD, et al.
    British Thoracic Society Guideline for bronchiectasis in adults. Thorax 2019; 74: Suppl. 1, 1–69. doi:10.1136/thoraxjnl-2018-212463
    OpenUrlFREE Full Text
  4. ↵
    1. Polverino E,
    2. Goeminne P,
    3. McDonnell M, et al.
    European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J 2017; 50: 1700629. doi:10.1183/13993003.00629-2017
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Chenoweth C,
    2. Washer L,
    3. Obeyesekera K, et al.
    Ventilator-associated pneumonia in the home care setting. Infect Control Hosp Epidemiol 2007; 28: 910–915. doi:10.1086/519179
    OpenUrlCrossRefPubMed
  6. ↵
    1. De Soyza A,
    2. Hall A,
    3. Mahenthiralingam E, et al.
    Developing an international Pseudomonas aeruginosa reference panel. MicrobiologyOpen 2013; 2: 1010–1023. doi:10.1002/mbo3.141
    OpenUrl
  7. ↵
    1. Gregson E,
    2. Thomas L,
    3. Elphick H
    . Pseudomonas aeruginosa infection in respiratory samples in children with neurodisability—to treat or not to treat? Eur J Pediatr 2021; 180: 2897–2905. doi:10.1007/s00431-021-04025-y
    OpenUrl
  8. ↵
    1. Priou P,
    2. Hamel JF,
    3. Person C, et al.
    Long-term outcome of noninvasive positive pressure ventilation for obesity hypoventilation syndrome. Chest 2010; 138: 84–90. doi:10.1378/chest.09-2472
    OpenUrlCrossRefPubMed
  9. ↵
    1. Masa JF,
    2. Benítez I,
    3. Sánchez-Quiroga MÁ, et al.
    Spanish Sleep Network. Long-term Noninvasive Ventilation in Obesity Hypoventilation Syndrome Without Severe OSA: The Pickwick Randomized Controlled Trial. Chest 2020; 158: 1176–1186. doi:10.1016/j.chest.2020.03.068
    OpenUrl
  10. ↵
    1. Quinlivan R,
    2. Messer B,
    3. Murphy P, et al.
    Adult North Star Network (ANSN): Consensus Guideline For The Standard Of Care Of Adults With Duchenne Muscular Dystrophy. J Neuromuscul Dis 2021; 8: 899–926. doi:10.3233/JND-200609
    OpenUrl
  11. ↵
    1. Hull J,
    2. Aniapravan R,
    3. Chan E, et al.
    British Thoracic Society guideline for respiratory management of children with neuromuscular weakness. Thorax 2012; 67: Suppl. 1, i1–i40. doi:10.1136/thoraxjnl-2012-201964
    OpenUrlFREE Full Text
  12. ↵
    1. Decker D,
    2. Fincham R
    . Respiratory arrest in myasthenia gravis with colistimethate therapy. Arch Neurol 1971; 25: 141–144. doi:10.1001/archneur.1971.00490020059006
    OpenUrlCrossRefPubMed
  13. ↵
    1. Russell C,
    2. Simon T,
    3. Mamey M, et al.
    Pseudomonas aeruginosa and post-tracheotomy bacterial respiratory tract infection readmissions. Pediatr Pulmonol 2017; 52: 1212–1218. doi:10.1002/ppul.23716
    OpenUrl
  14. ↵
    1. McCaleb R,
    2. Warren R,
    3. Willis D, et al.
    Description of respiratory microbiology of children with long-term tracheostomies. Respir Care 2015; 61: 447–452. doi:10.4187/respcare.03518
    OpenUrl
  15. ↵
    1. Donlan R,
    2. Costerton J
    . Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002; 15: 167–193. doi:10.1128/CMR.15.2.167-193.2002
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Raveendra N,
    2. Rathnakara S,
    3. Haswani N, et al.
    Bacterial biofilms on tracheostomy tubes. Indian J Otolaryngol Head Neck Surg 2021; in press [https://doi.org/10.1007/s12070-021-02598-6].
  17. ↵
    1. Sottile F,
    2. Marrie T,
    3. Prough D, et al.
    Nosocomial pulmonary infection. Crit Care Med 1986; 14: 265–270. doi:10.1097/00003246-198604000-00001
    OpenUrlCrossRefPubMed
  18. ↵
    1. Windisch W
    . Impact of home mechanical ventilation on health-related quality of life. Eur Respir J 2008; 32: 1328–1336. doi:10.1183/09031936.00066407
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Eklöf J,
    2. Sørensen R,
    3. Ingebrigtsen T, et al.
    Pseudomonas aeruginosa and risk of death and exacerbations in patients with chronic obstructive pulmonary disease: an observational cohort study of 22 053 patients. Clin Microbiol Infect 2020; 26: 227–234. doi:10.1016/j.cmi.2019.06.011
    OpenUrlPubMed
PreviousNext
Back to top
Vol 8 Issue 2 Table of Contents
ERJ Open Research: 8 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
An observational study of Pseudomonas aeruginosa in adult long-term ventilation
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
An observational study of Pseudomonas aeruginosa in adult long-term ventilation
Ruth Sobala, Hannah Carlin, Thomas Fretwell, Sufyan Shakir, Katie Cattermole, Amy Royston, Paul McCallion, John Davison, Joanna Lumb, Hilary Tedd, Ben Messer, Anthony De Soyza
ERJ Open Research Apr 2022, 8 (2) 00687-2021; DOI: 10.1183/23120541.00687-2021

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
An observational study of Pseudomonas aeruginosa in adult long-term ventilation
Ruth Sobala, Hannah Carlin, Thomas Fretwell, Sufyan Shakir, Katie Cattermole, Amy Royston, Paul McCallion, John Davison, Joanna Lumb, Hilary Tedd, Ben Messer, Anthony De Soyza
ERJ Open Research Apr 2022, 8 (2) 00687-2021; DOI: 10.1183/23120541.00687-2021
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Material and methods
    • Results
    • Discussion
    • Supplementary material
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • CF and non-CF bronchiectasis
  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Original research articles

  • Volatile metabolites of pulmonary oxidative injury
  • Assessment of mycobacterial burden in NTM treatment
  • Anti-IL-5 antibody therapy and exercise testing
Show more Original research articles

Respiratory infections

  • Assessment of mycobacterial burden in NTM treatment
  • Group-based pulmonary telerehabilitation for COVID-19
  • Pulmonary outcomes and CT the first year after COVID-19
Show more Respiratory infections

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About ERJ Open Research

  • Editorial board
  • Journal information
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Online ISSN: 2312-0541

Copyright © 2023 by the European Respiratory Society